



Cushing's at the Core: Leading-Edge Strategies for Diagnosis and Medical Management of Cushing Syndrome/Hypercortisolism

ACC. Prevalence And Clinical Impact Of Hypercortisolism In Individuals With Resistant Hypertension: Primary Results From The Momentum Study. <https://accscientificsession.acc.org/Plan-Your-Program/EducationSessions/Late-Breakers>. Accessed February 2026.

Afandi B, Toumeh MS, Saadi HF. Cushing's syndrome caused by unsupervised use of ocular glucocorticoids. *Endocr Pract*. 2003;9(6):526-529.

Armstrong RD, English J, Gibson T, et al. Serum methylprednisolone levels following intra-articular injection of methylprednisolone acetate. *Ann Rheum Dis*. 1981;40(6):571-574.

Araujo-Castro M, Bancos I, Detomas M, et al. International Real-world study on osilodrostat efficacy and safety in adrenal Cushing syndrome. *J Clin Endocrinol Metab*. 2026:dga115.

Araujo-Castro M, García-Centeno R, González L, et al. Real-world data on the efficacy and safety of osilodrostat in patients with Cushing's Disease in Spain. *J Clin Med*. 2025; 14(21):7575.

Aresta C, Soranna D, Giovanelli L, et al. When to suspect hidden hypercortisolism in type 2 diabetes: a meta-analysis. *Endocr Pract*. 2021;27(12):1216-1224.

Babic N, Yeo KTJ, Hannoush ZC, Weiss RE. Endocrine testing protocols: hypothalamic pituitary adrenal axis. 2023 Aug 7. In: Feingold KR, Adler RA, Ahmed SF, et al, editors. *Endotext* [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. PMID: 25905177.

Bancos I, Castinetti F, Brevoort Geer E, et al. SUN-054 Long-term, real-world, safety and effectiveness of osilodrostat in patients with pituitary and non-pituitary Cushing's syndrome: 2-Year interim data from LINC 6. *J Endocr Soc*. 2025;9(Suppl 1):bvaf149.1639.

Bansal V, El Asmar N, Selman WR, Arafah BM. Pitfalls in the diagnosis and management of Cushing's syndrome. *Neurosurg Focus*. 2015;38(2):E4.

Bhatt DL, Taub P, Laffin L, et al. Prevalence and clinical impact of hypercortisolism in individuals with resistant hypertension: primary results from the Momentum Study. Presented at American College of Cardiology's Annual Scientific Session (ACC.26). March 27-30, 2026. New Orleans, LA. Available at: ACC 75th Annual Scientific Sessions - Prevalence And Clinical Impact Of Hypercortisolism In Individuals With Resistant Hypertension: Primary Results From The Momentum Study. Accessed April 2026.

Buse JB, Kahn SE, Aroda VR, et al; CATALYST Investigators*. Prevalence of hypercortisolism in difficult-to-control type 2 diabetes. *Diabetes Care*. 2025;48(12):2012-2020.

Cannizzaro E, Cirrincione L, Mazzucco W, et al. Night-time shift work and related stress responses: a study on security guards. *Int J Environ Res Public Health*. 2020;17(2):562.

Casals G, Hanzu FA. Cortisol measurements in Cushing's syndrome: immunoassay or mass spectrometry? *Ann Lab Med*. 2020;40(4):285-296.

Catargi B, Rigalleau V, Poussin A, et al. Occult Cushing's syndrome in type-2 diabetes. *J Clin Endocrinol Metab*. 2003;88(12):5808-5813.

Ceccato F, Terzolo M, Gatto F, et al. Who and how to screen for Cushing's syndrome: the position statement of the Italian Society of Endocrinology. *J Endocrinol Invest*. 2026;49(3):461-481.



Bibliography and Suggested Reading

Cushing's at the Core: Leading-Edge Strategies for Diagnosis and Medical Management of Cushing Syndrome/Hypercortisolism

Chan KC, Lit LC, Law EL, et al. Diminished urinary free cortisol excretion in patients with moderate and severe renal impairment. *Clin Chem*. 2004;50(4):757-759.

Chiodini I, Torlontano M, Scillitani A, et al. Association of subclinical hypercortisolism with type 2 diabetes mellitus: a case-control study in hospitalized patients. *Eur J Endocrinol*. 2005;153(6):837-844.

Cohan P. Pasireotide and mifepristone: new options in the medical management of Cushing's disease. *Endocr Pract*. 2014;20(1):84-93.

Colao A, Petersenn S, Newell-Price J, et al; Pasireotide B2305 Study Group. A 12-month phase 3 study of pasireotide in Cushing's disease. *N Engl J Med*. 2012;366(10):914-924.

Contreras LN, Cardoso E, Lozano MP, et al. Detección de síndrome de Cushing preclínico en pacientes con sobrepeso y diabetes mellitus tipo 2 [Detection of preclinical Cushing's syndrome in overweight type 2 diabetic patients]. *Medicina (B Aires)*. 2000;60(3):326-330.

Costa DS, Conceição FL, Leite NC, et al. Prevalence of subclinical hypercortisolism in type 2 diabetic patients from the Rio de Janeiro Type 2 Diabetes Cohort Study. *J Diabetes Complications*. 2016;30(6):1032-1038.

Czerwiec FS, Fernandez EV, Katz DA. 1807-P: Cardiometabolic Effects of Clotubripen (CLO) in Adults with Type 2 Diabetes (T2D): A Six-Week, Phase 2, Placebo-Controlled, Randomized Clinical Trial. *Diabetes*. 2026;75 (Supplement_1):1807-P.

DeFronzo RA, Fonseca V, Aroda VR, et al, CATALYST Investigators*. Inadequately controlled type 2 diabetes and hypercortisolism: improved glycemia with mifepristone treatment. *Diabetes Care*. 2025;48(12):2036-2044.

Fallo F, Paoletta A, Tona F, Boscaro M, Sonino N. Response of hypertension to conventional antihypertensive treatment and/or steroidogenesis inhibitors in Cushing's syndrome. *J Intern Med*. 1993;234(6):595-598.

Feelders RA, Newell-Price J, Pivonello R, et al. Advances in the medical treatment of Cushing's syndrome. *Lancet Diabetes Endocrinol*. 2019;7(4):300-312.

Feelders RA, Fleseriu M, Kadioglu P, et al. Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing's disease. *Front Endocrinol (Lausanne)*. 2023;14:1165681.

Fleseriu M, et al. Consensus on diagnosis and management of Cushing's disease: a guideline update. *Lancet Diabetes Endocrinol*. 2021;9:847-875.

Fleseriu M, Varlamov EV, Hinojosa-Amaya JM, et al. An individualized approach to the management of Cushing disease. *Nat Rev Endocrinol*. 2023;19(10):581-599.

Fleseriu M, et al. Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial. *Lancet Diabetes Endocrinol*. 2019;7:855-865.

Fleseriu M, Biller BM, Findling JW, et al; SEISMIC Study Investigators. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. *J Clin Endocrinol Metab*. 2012;97(6):2039-49.

Fleseriu M, Pivonello R, Elenkova A, et al. Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial. *Lancet Diabetes Endocrinol*. 2019;7(11):855-865.



Cushing's at the Core: Leading-Edge Strategies for Diagnosis and Medical Management of Cushing Syndrome/Hypercortisolism

Fleseriu M, Badiu CP, Bancos I, et al. OR12-04 Clofutriben, an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor, vs placebo in a phase II trial for ACTH-dependent Cushing's syndrome (RESCUE). *J Endocr Soc.* 2025;9(Suppl 1):bvaf149.1471.

Fleseriu M, Auchus RJ, Greenman Y, et al. Levoketoconazole treatment in endogenous Cushing's syndrome: extended evaluation of clinical, biochemical, and radiologic outcomes. *Eur J Endocrinol.* 2022;187(6):859-871.

Fleseriu M, Biller BMK, Bertherat J, et al. Long-term efficacy and safety of osilodrostat in Cushing's disease: final results from a Phase II study with an optional extension phase (LINC 2). *Pituitary.* 2022;25(6):959-970.

Fleseriu M, Newell-Price J, Pivonello R, et al. Long-term outcomes of osilodrostat in Cushing's disease: LINC 3 study extension. *Eur J Endocrinol.* 2022;187(4):531-541.

Fleseriu M, Pivonello R, Newell-Price J, et al. Osilodrostat improves blood pressure and glycemic control in patients with Cushing's disease: a pooled analysis of LINC 3 and LINC 4 studies. *Pituitary.* 2025;28(1):22.

Fleseriu M, et al. Effect of dosing and titration of osilodrostat on efficacy and safety in patients with Cushing's disease (CD): Results from two phase III trials (LINC3 and LINC4). Presented at AACE 2021. Available at: Giraldi EA, Ioachimescu AG. The Role of Dopamine Agonists in Pituitary Adenomas. *Endocrinol Metab Clin North Am.* 2020;49(3):453-474. .

Flowers KC, Shipman KE. Pitfalls in the diagnosis and management of hypercortisolism (Cushing syndrome) in humans; a review of the laboratory medicine perspective. *Diagnostics (Basel).* 2023;13(8):1415.

Gadelha M, Bex M, Feelders RA, et al. Randomized trial of osilodrostat for the treatment of Cushing disease. *J Clin Endocrinol Metab.* 2022;107(7):e2882-e2895.

Gadelha M, Gatto F, Wildemberg LE, Fleseriu M. Cushing's syndrome. *Lancet.* 2023;402(10418):2237-2252.

Gadelha M, Snyder PJ, Witek P, et al. Long-term efficacy and safety of osilodrostat in patients with Cushing's disease: results from the LINC 4 study extension. *Front Endocrinol (Lausanne).* 2023;14:1236465.

Giovanelli L, Aresta C, Favero V, et al. Hidden hypercortisolism: a too frequently neglected clinical condition. *J Endocrinol Invest.* 2021;44(8):1581-1596.

Hinojosa-Amaya JM, Cuevas-Ramos D, Fleseriu M. Medical management of Cushing's syndrome: cCurrent and emerging treatments. *Drugs.* 2019;79(9):935-956.

Invitti C, Pecori Giraldi F, de Martin M, Cavagnini F. Diagnosis and management of Cushing's syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. *J Clin Endocrinol Metab.* 1999;84(2):440-448.

Jabbour S, Arnaldi G, Auchus R, et al. Relacorilant on blood pressure and antihypertensive medication burden in patients with hypercortisolism and hypertension: results from the GRACE study. Poster Presented at Heart in Diabetes June 6-8, 2025. Abstract 0097.

Jing Y, Hu J, Luo R, et al. Prevalence and characteristics of adrenal tumors in an unselected screening population: a cross-sectional study. *Ann Intern Med.* 2022;175(10):1383-1391.

Jusufović S, Halilčević A, Jusufović R, et al. The prevalence of hypercortisolism in patients with type 2 diabetes and microvascular complications: a prospective observational case-control study. *Clinical Diabetology.* 2024;13(5):246-253.



Bibliography and Suggested Reading

Cushing's at the Core: Leading-Edge Strategies for Diagnosis and Medical Management of Cushing Syndrome/Hypercortisolism

Katz HI, Hien NT, Prawer SE, et al. Superpotent topical steroid treatment of psoriasis vulgaris--clinical efficacy and adrenal function. *J Am Acad Dermatol*. 1987;16(4):804-811.

Kidambi S, Raff H, Findling JW. Limitations of nocturnal salivary cortisol and urine free cortisol in the diagnosis of mild Cushing's syndrome. *European J Endocrinol*. 2007;157: 725-731.

Lacroix A, Gu F, Gallardo W, et al; Pasireotide G2304 Study Group. Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial. *Lancet Diabetes Endocrinol*. 2018;6(1):17-26.

Leibowitz G, Tsur A, Chayen SD, et al. Pre-clinical Cushing's syndrome: an unexpected frequent cause of poor glycaemic control in obese diabetic patients. *Clin Endocrinol (Oxf)*. 1996;44(6):717-722.

León-Justel A, Madrazo-Atutxa A, Alvarez-Rios AI, et al; Spanish CRISALIDA Study Group. A probabilistic model for Cushing's syndrome screening in at-risk populations: a prospective multicenter study. *J Clin Endocrinol Metab*. 2016;101(10):3747-3754.

Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. *Arch Intern Med*. 1999;159(9):941-955.

Limumpornpetch P, Morgan AW, Tiganescu A, et al. The effect of endogenous Cushing syndrome on all-cause and cause-specific mortality. *J Clin Endocrinol Metab*. 2022;107(8):2377-2388.

Martino M, Aboud N, Lucchetti B, et al. An evaluation of pharmacological options for Cushing's disease: what are the state-of-the-art options? *Expert Opin Pharmacother*. 2023;24(5):557-576.

Miller WR, et al. Enhancing Motivation for Change in Substance Use Disorder Treatment: Updated 2019 [Internet]. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK571068/>. Accessed February 11, 2026.

Newell-Price J, Pivonello R, Tabarin A, et al. Use of late-night salivary cortisol to monitor response to medical treatment in Cushing's disease. *Eur J Endocrinol*. 2020;182(2):207-217.

Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2008;93(5):1526-1540.

Nieman LK. Recent updates on the diagnosis and management of Cushing's syndrome. *Endocrinol Metab (Seoul)*. 2018;33:139-146.

Nieman LK, Biller BM, Findling JW, et al; Endocrine Society. Treatment of Cushing's syndrome: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab*. 2015;100(8):2807-2831.

Plutzky J, Taub PR, Bhatt DL, et al. Investigating endogenous hypercortisolism prevalence in a U.S. population with resistant hypertension: MOMENTUM rationale and design. *JACC Adv*. 2026;5(3):102596.

Pivonello R, Zacharieva S, Elenkova A, et al. Levoketoconazole in the treatment of patients with endogenous Cushing's syndrome: a double-blind, placebo-controlled, randomized withdrawal study (LOGICS). *Pituitary*. 2022;25(6):911-926.

Pivonello R, Bancos I, Feelders RA, et al. Relacorilant, a selective glucocorticoid receptor modulator, induces clinical improvements in patients with Cushing syndrome: results from a prospective, open-label phase 2 study. *Front Endocrinol*. 2021;12:555894.



Cushing's at the Core: Leading-Edge Strategies for Diagnosis and Medical Management of Cushing Syndrome/Hypercortisolism

Pivonello R, Isidori AM, De Martino MC, et al. Complications of Cushing's syndrome: state of the art. *Lancet Diabetes Endocrinol.* 2016;4(7):611-629.

Pivonello R, Arnaldi G, Auchus R, et al. Medical treatment of hypercortisolism with relacorilant: Final results of the phase 3 GRACE study. *Endocrine Abstracts.* 2025;110:P69.

Pivonello R, Arnaldi G, Auchus RJ, et al. 9323 Open-label results from Grace, a phase 3 double-blind, randomized-withdrawal study of the selective glucocorticoid receptor modulator relacorilant for the treatment of endogenous hypercortisolism (Cushing syndrome). *J Endocr Soc.* 2024;8(Suppl 1):bvae163.1287.

Pivonello R, Arnaldi G, Auchus RJ, et al; GRACE Study Investigators. Efficacy and safety of relacorilant for the treatment of patients with Cushing's syndrome (GRACE): a multicentre, phase 3, double-blind, placebocontrolled, randomised-withdrawal study. *Lancet Diabetes Endocrinol.* 2026:S2213-8587(25):00362-00366.

Pivonello R, Fleseriu M, Newell-Price J, et al; LINC 3 investigators. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. *Lancet Diabetes Endocrinol.* 2020;8(9):748-761.

Pivonello R, Ferrigno R, De Martino MC, Set al. Medical treatment of Cushing's disease: an overview of the current and recent clinical trials. *Front Endocrinol (Lausanne).* 2020 8;11:648.

Raff H, Sharma ST, Nieman LK. Physiological basis for the etiology, diagnosis, and treatment of adrenal disorders: Cushing's syndrome, adrenal insufficiency, and congenital adrenal hyperplasia. *Compr Physiol.* 2014;4(2):739-769.

Reincke M, Fleseriu M. Cushing syndrome: a review. *JAMA.* 2023;330(2):170-181.

Ritzel K, Fazel J, August L, et al. Biochemical control in Cushing's syndrome: outcomes of the treatment in a large single center cohort. *J Clin Endocrinol Metab.* 2025;110(4):e1038-e1045.

Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology Consensus Statement: Algorithm for management of adults with type 2 diabetes - 2026 update. *Endocr Pract.* 2026:S1530-891X(26)00022-4.

Samson SL. Long-term medical treatment of Cushing's disease with pasireotide: a review of current evidence and clinical experience. *Exp Clin Endocrinol Diabetes.* 2014;122(8):445-450.

Sandooja R, Hamidi O, Zhang CD, et al. Bilateral adrenal nodules presenting with mild autonomous cortisol secretion. *Endocr Pract.* 2025;31(8):1071-1083.

Scaroni C, Zilio M, Foti M, Boscaro M. Glucose metabolism abnormalities in Cushing syndrome: from molecular basis to clinical management. *Endocr Rev.* 2017;38(3):189-219.

Sharma ST, Nieman LK, Feelders RA. Cushing's syndrome: epidemiology and developments in disease management. *Clin Epidemiol.* 2015;7:281-293.

Silverstein JM. Hyperglycemia induced by pasireotide in patients with Cushing's disease or acromegaly. *Pituitary.* 2016;19(5):536-543.

Silverstein J, Dobri G, Elenkova A, et al. Relacorilant Treatment Improves Glycemic Control Among Individuals With Cushing Syndrome (Endogenous Hypercortisolism) and Hyperglycemia on Glucagon-Like Peptide-1 Receptor Agonists: Insights From a Phase 3 Study. *Endocrine Practice.* 2026;32(4 Supplement):S215-S216.



Bibliography and Suggested Reading

Cushing's at the Core: Leading-Edge Strategies for Diagnosis and Medical Management of Cushing Syndrome/Hypercortisolism

Sloan L, Aroda V, Busch RS, et al. 1219-OR: Effects of Mifepristone in People with Difficult-to-Control T2D and Hypercortisolism on GLP-1RAs. *Diabetes*. 2026;75 (Supplement_1):1219-OR.

Steffensen C, Dekkers OM, Lyhne J, et al. Hypercortisolism in newly diagnosed type 2 diabetes: a prospective study of 384 newly diagnosed patients. *Horm Metab Res*. 2019;51(1):62-68.

Taniguchi T, Hamasaki A, Okamoto M. Subclinical hypercortisolism in hospitalized patients with type 2 diabetes mellitus. *Endocr J*. 2008;55(2):429-432.

Tritos NA, Biller BM, Swearingen B. Management of Cushing disease. *Nat Rev Endocrinol*. 2011;7(5):279-289.